Pleiotropic effects of statins - PubMed (original) (raw)
Review
Pleiotropic effects of statins
James K Liao et al. Annu Rev Pharmacol Toxicol. 2005.
Abstract
Statins are potent inhibitors of cholesterol biosynthesis. In clinical trials, statins are beneficial in the primary and secondary prevention of coronary heart disease. However, the overall benefits observed with statins appear to be greater than what might be expected from changes in lipid levels alone, suggesting effects beyond cholesterol lowering. Indeed, recent studies indicate that some of the cholesterol-independent or "pleiotropic" effects of statins involve improving endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response. Furthermore, statins have beneficial extrahepatic effects on the immune system, CNS, and bone. Many of these pleiotropic effects are mediated by inhibition of isoprenoids, which serve as lipid attachments for intracellular signaling molecules. In particular, inhibition of small GTP-binding proteins, Rho, Ras, and Rac, whose proper membrane localization and function are dependent on isoprenylation, may play an important role in mediating the pleiotropic effects of statins.
Figures
Figure 1
Structural basis of HMG-CoA reductase inhibition by statins. The active forms of statins resemble the cholesterol precursor, HMG-CoA (right panels). All statins share the HMG-like moiety and competitively inhibit the reductase by the similar mechanism but have distinct pharmacologic and pharmacodynamic properties related to their chemical structures (left panels, ball and stick graphs: black, carbon; red, oxygen; light blue, hydrogen; dark blue, nitrogen).
Figure 2
Biological actions of isoprenoids. Diagram of cholesterol biosynthesis pathway showing the effects of inhibition of HMG-CoA reductase by statins. Decrease in isoprenylation of signaling molecules, such as Ras, Rho, and Rac, leads to modulation of various signaling pathways. BMP-2: bone morphogenetic protein-2; eNOS: endothelial nitric oxide synthase; t-PA: tissue-type plasminogen activator; ET-1: endothelin-1; PAI-1: plasminogen activator inhibitor-1.
Figure 3
Regulation of Rho GTPase by isoprenylation. Rho proteins change between a cytosolic, inactive, GDP-bound state and an active, membrane, GTP-bound state. This cycle is controlled by several cofactors, including guanine nucleotide exchange factors (GEF), GTPase-activating proteins (GAP), and guanine nucleotide dissociation inhibitors (GDI). An important step in the activation of Rho GTPases is the posttranslational isoprenylation, which allows the translocation of Rho to the cell membrane and the subsequent activation.
Figure 4
Antioxidative mechanisms of statins. The core NAD(P)H oxidase comprises five components: p40_phox_ (PHOX for phagocyte oxidase), p47_phox_, p67_phox_, p22_phox_, and gp91_phox_. In the resting cell (left), three of these five components, p40_phox_, p47_phox_, and p67_phox_,exist in the cytosol as a complex. The other two components, p22_phox_ and gp91_phox_, are located in the membranes. When it is stimulated by angiotensin, the cytosolic component becomes heavily phosphorylated and the entire cytosolic complex migrates to the membrane. Activation requires the participation not only of the core subunits but also of two low-molecular-weight guanine nucleotide-binding proteins, Rac and Rap. During activation, Rac binds GTP and migrates to the membrane along with the core cytosolic complex. Treatment with statin down-regulates AT1-receptor expression and inhibits Rac1 GTPase, a necessary component of the NAD(P)H oxidase complex.
Figure 5
Relationship between LDL-C reduction and risk of cardiovascular events. (Left panel) Decrease in LDL-C (% reduction) is correlated with reduction in risk of nonfatal myocardial infarctions (MI) or coronary heart disease (CHD) among statin (WOSCOPS, CARE, and 4S) and nonstatin (LRC-CPPT and POSCH) trials. Note that the relationship (slope) holds between statin and nonstatin trials, suggesting that the beneficial effects of statins are likely due to only cholesterol lowering. (Right panel) Decrease in LDL-C (% reduction) is correlated with reduction in risk of nonfatal myocardial infarctions (MI) or coronary heart disease (CHD) among statin (WOSCOPS, CARE, and 4S) and nonstatin (LRC-CPPT and POSCH) trials after 4.5 years of treatment. Note that the nonstatin trials (LRC-CPPT and POSCH; dashed lines) show less cardiovascular benefits than statin trials (WOSCOPS, CARE, and 4S) and they no longer fall on the same slope (solid line).
Similar articles
- Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.
Liao JK. Liao JK. Am J Cardiol. 2005 Sep 5;96(5A):24F-33F. doi: 10.1016/j.amjcard.2005.06.009. Am J Cardiol. 2005. PMID: 16126020 Free PMC article. Review. - Clinical implications for statin pleiotropy.
Liao JK. Liao JK. Curr Opin Lipidol. 2005 Dec;16(6):624-9. doi: 10.1097/01.mol.0000191913.16321.60. Curr Opin Lipidol. 2005. PMID: 16276239 Review. - Antioxidative effects of statins.
Adam O, Laufs U. Adam O, et al. Arch Toxicol. 2008 Dec;82(12):885-92. doi: 10.1007/s00204-008-0344-4. Epub 2008 Aug 1. Arch Toxicol. 2008. PMID: 18670762 Review. - Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
Takemoto M, Liao JK. Takemoto M, et al. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9. doi: 10.1161/hq1101.098486. Arterioscler Thromb Vasc Biol. 2001. PMID: 11701455 Review. - Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J. Lahera V, et al. Curr Med Chem. 2007;14(2):243-8. doi: 10.2174/092986707779313381. Curr Med Chem. 2007. PMID: 17266583 Review.
Cited by
- Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions.
Mitsis A, Myrianthefs M, Sokratous S, Karmioti G, Kyriakou M, Drakomathioulakis M, Tzikas S, Kadoglou NPE, Karagiannidis E, Nasoufidou A, Fragakis N, Ziakas A, Kassimis G. Mitsis A, et al. Biomedicines. 2024 Jul 26;12(8):1670. doi: 10.3390/biomedicines12081670. Biomedicines. 2024. PMID: 39200135 Free PMC article. Review. - Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study.
Lee J, Choi JY, Choi BG, Choi YJ, Park S, Kang DO, Park EJ, Kim JB, Roh SY, Na JO, Choi CU, Kim EJ, Park CG, Jeong MH, Hwang JY, Hur SH, Jeong JO, Oh S, Rha SW; KAMIR NIH Investigators. Lee J, et al. Sci Rep. 2024 Aug 21;14(1):19438. doi: 10.1038/s41598-024-67585-7. Sci Rep. 2024. PMID: 39169014 Free PMC article. - High - but not standard-dose atorvastatin prevents the increase of plasma matrix metalloproteinase-2 triggered by acute coronary syndromes.
Paciullo F, Falcinelli E, Fierro T, Gresele P, Del Pinto M. Paciullo F, et al. Coron Artery Dis. 2024 Nov 1;35(7):622-624. doi: 10.1097/MCA.0000000000001414. Epub 2024 Sep 19. Coron Artery Dis. 2024. PMID: 39087641 Free PMC article. No abstract available. - Porcelain Aorta and Quadruple Extracranial Vessel Occlusion: A Case of Minimal Neurological Deficits Despite Severe Vascular Blockages.
Golchin Vafa R, Hosseini N, Montaseri M, Kojuri J. Golchin Vafa R, et al. Am J Case Rep. 2024 Jul 29;25:e944099. doi: 10.12659/AJCR.944099. Am J Case Rep. 2024. PMID: 39069697 Free PMC article. - Anti-Inflammatory Effect of Atorvastatin and Rosuvastatin on Monosodium Urate-Induced Inflammation through IL-37/Smad3-Complex Activation in an In Vitro Study Using THP-1 Macrophages.
Kim SK, Choe JY, Kim JW, Park KY, Kim B. Kim SK, et al. Pharmaceuticals (Basel). 2024 Jul 3;17(7):883. doi: 10.3390/ph17070883. Pharmaceuticals (Basel). 2024. PMID: 39065733 Free PMC article.
References
- Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int. J. Cardiol. 1997;62 Suppl 2:S23–S29. - PubMed
- Sytkowski PA, Kannel WB, D’Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. New Engl. J. Med. 1990;322:1635–1641. - PubMed
- Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham Study. JAMA. 1971;215:1617–1625. - PubMed
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. - PubMed
- Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl. J. Med. 1996;335:1001–1009. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 NS010828/NS/NINDS NIH HHS/United States
- R01 DK062729-01A1/DK/NIDDK NIH HHS/United States
- R01 HL070274-02/HL/NHLBI NIH HHS/United States
- P01 HL048743/HL/NHLBI NIH HHS/United States
- P01 NS010828-330036/NS/NINDS NIH HHS/United States
- R01 DK062729-02/DK/NIDDK NIH HHS/United States
- R01 HL052233-05/HL/NHLBI NIH HHS/United States
- R01 HL070274-01/HL/NHLBI NIH HHS/United States
- NS-10828/NS/NINDS NIH HHS/United States
- R01 HL052233-07/HL/NHLBI NIH HHS/United States
- P50 NS010828/NS/NINDS NIH HHS/United States
- F32 NS010828/NS/NINDS NIH HHS/United States
- HL-48743/HL/NHLBI NIH HHS/United States
- R01 HL052233-06/HL/NHLBI NIH HHS/United States
- R01 HL052233/HL/NHLBI NIH HHS/United States
- R01 DK062729/DK/NIDDK NIH HHS/United States
- R01 HL070274/HL/NHLBI NIH HHS/United States
- R01 HL070274-03/HL/NHLBI NIH HHS/United States
- P50 NS010828-290036/NS/NINDS NIH HHS/United States
- HL-52233/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous